Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study)

Role of Bempedoic Acid in Clinical Practice

(2021) Christie M. Ballantyne et al.   CARDIOVASCULAR DRUGS AND THERAPY

Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

(2020) Arrigo F. G. Cicero et al.   PLOS MEDICINE

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia

(2020) Maciej Banach et al.   JAMA Cardiology

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance

(2020) Stephen J Nicholls et al.   AMERICAN HEART JOURNAL

Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials

(2020) Harold E. Bays et al.   Journal of Clinical Lipidology

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

(2019) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mendelian Randomization Study of ACLY and Cardiovascular Disease

(2019) Brian A. Ference et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance

(2019) Ulrich Laufs et al.   Journal of the American Heart Association

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease

(2019) Anne C. Goldberg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

(2018) Christie M. Ballantyne et al.   ATHEROSCLEROSIS

Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes – Data from the TERCET registry with 19,287 patients

(2018) Krzysztof Dyrbus et al.   PHARMACOLOGICAL RESEARCH

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

(2014) S. Matthijs Boekholdt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY